stockrow
Friday 6 November 2026
Export SERA’s income statement to Excel — free account
Sera Prognostics, Inc.
SERA Healthcare Medical Devices
Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024.
- Revenue
- +162.5%
- EPS
- +0.88%
- Free cash flow
- −12.8%
Quarter to September 2026, against a year earlier
2.16
0.08
+3.85%
Follow SERA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1,735.84 | 1,789.92 | 1,312.40 | 1,105.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.97) | (11.63) | (14.56) | (14.55) | |
P/B ratio |
1.86 | 1.51 | 1.55 | 2.02 | |
Price to Tangible BV |
1.89 | 1.53 | 1.57 | 2.06 | |
EV/Sales |
1,251.90 | 958.36 | 648.93 | 646.50 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.96) | (2.03) | (1.64) | (2.18) | |
EV/FCF |
(3.70) | (1.91) | (1.59) | (2.11) | |
Quick Ratio |
1.62 | 2.02 | 1.91 | 1.80 | |
Current Ratio |
1.69 | 2.12 | 1.98 | 1.88 | |
Net Debt/EBITDA |
4.50 | 5.17 | 4.73 | 5.07 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.78 | 1.04 | 0.69 | 0.91 | |
Capex/Depreciation |
(1.35) | (0.04) | (0.27) | (0.70) | |
Interest Coverage |
(8,954.00) | (4,680.00) | (5,002.00) | (4,443.50) | |
Research and Development Expense of Revenue |
32,160.00% | 21,642.86% | 11,643.33% | 6,480.95% | |
Selling, General and Administrative Expense of Revenue |
57,060.00% | 45,014.29% | 21,636.67% | 14,633.33% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
10,190.00% | 5,964.29% | 2,743.33% | 3,050.00% | |
Graham Net Nets |
0.10 | 0.23 | 0.23 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.05%) | (32.02%) | (36.81%) | (31.99%) | |
Free Cash Flow Yield |
(19.48%) | (28.05%) | (31.06%) | (27.67%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.17) | (0.12) | (0.14) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.14) | (0.17) | (0.13) | (0.15) | |
Cash per Share |
0.82 | 0.94 | 0.92 | 0.87 | |
Shareholders Equity per Share |
1.58 | 1.35 | 1.18 | 1.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.58 | 1.35 | 1.18 | 1.03 | |
Free Cash Flow |
(6.45) | (8.78) | (6.36) | (7.43) | |
Working Capital |
16.58 | 26.31 | 23.78 | 21.69 | |
Capital Expenditures |
(0.33) | (0.01) | (0.05) | (0.13) | |
Net Current Asset Value |
14.25 | 23.80 | 20.78 | 18.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
33.00 | 0.57 | 1.73 | 3.19 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.02 | 0.01 | 0.02 | |
Average Payables |
1.42 | 0.99 | 1.13 | 1.10 | |
Average Assets |
87.25 | 105.86 | 99.28 | 94.05 | |
Average Common Equity |
61.61 | 81.20 | 73.80 | 67.31 |
Columns are period end dates · fundamentals updated 6 Nov 2026